Patents Examined by Jeffrey S. Parkin
  • Patent number: 10209257
    Abstract: The present invention relates to a method for detecting and/or quantifying human immunodeficiency virus (HIV) specific antibodies in a sample of a subject comprising the step of determining the presence and/or amount of antibodies binding to a) a peptide consisting of the amino acid sequence AIVCTRPNNNTRKSIRIGPGQVFYT (SEQ ID No. 1), or b) a homolog having at least 70% identity with a peptide of a), or c) a fragment of a peptide of a) or b) consisting of 15 to 24 amino acid residues in said sample.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: February 19, 2019
    Assignee: Viravaxx AG
    Inventors: Rudolf Valenta, Daniela Gallerano, Elopy N. Sibanda
  • Patent number: 10195277
    Abstract: This invention provides compositions and methods to treat a condition or disease without the use of exogenous targeting sequences or chemical compositions. The present invention relates to single-domain antibodies (sdAbs), proteins and polypeptides comprising the sdAbs that are directed against targets that cause a condition or disease. The invention also includes nucleic acids encoding the sdAbs, proteins and polypeptides, and compositions comprising the sdAbs. The invention includes the use of the compositions, sdAbs, and nucleic acids encoding the sdAbs for prophylactic, therapeutic or diagnostic purposes.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: February 5, 2019
    Assignee: Singh Biotechnology, LLC
    Inventor: Sunanda Singh
  • Patent number: 10160788
    Abstract: The invention features stabilized human immunodeficiency virus (HIV) envelope (Env) trimers. The invention also features vaccines, nucleic acids, and vectors to deliver and/or facilitate production of the stabilized HIV Env trimers. In addition, the invention features methods of making and using the stabilized HIV Env trimers of the invention.
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: December 25, 2018
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Dan H. Barouch, Joseph Patrick Nkolola
  • Patent number: 10149888
    Abstract: The present invention relates to a novel use of the HIV NC protein, and more particularly, it is relates to a pharmaceutical composition for preventing and treating AIDS having a polypeptide comprising HIV NC protein as an active component and the method of inhibiting HIV proliferation by using the polypeptide. The polypeptide comprising HIV NC protein of the present invention, when it is overexpressed, has the effect on inhibiting HIV proliferation. Accordingly, the present invention provides not only the novel means of inhibition of HIV proliferation, but also the novel method for preventing and treating AIDS.
    Type: Grant
    Filed: February 13, 2008
    Date of Patent: December 11, 2018
    Assignees: AVIXGEN INC.
    Inventor: Ji Chang You
  • Patent number: 10137173
    Abstract: Compositions and methods are provided for treating viral infection in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL, MER or Tyro3 protein activity, for example by inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: November 27, 2018
    Assignee: Aravive Biologics, Inc.
    Inventor: Raymond Tabibiazar
  • Patent number: 10124059
    Abstract: The present invention relates to novel peptides and methods for inducing an immune response in a subject against an antigen and for treatment, diagnosis and prognosis of infections or autoimmune diseases including infections with HCV, HIV, CMV and Flu. The invention further relates to methods for identifying and providing peptides useful for the treatment and diagnosis.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: November 13, 2018
    Assignee: BIONOR IMMUNO AS
    Inventors: Einar Tønnes Lange, Maja Sommerfelt Grønvold, Birger Sørensen, Karolina Lawitz
  • Patent number: 10117924
    Abstract: The present invention provides compositions and methods of use comprising a chimeric dengue virus E glycoprotein comprising a dengue virus E glycoprotein backbone, which comprises amino acid substitutions that introduce a dengue virus E glycoprotein domain I and domain II hinge region from a dengue virus serotype that is different from the dengue virus serotype of the dengue virus E glycoprotein backbone.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: November 6, 2018
    Assignees: The University of North Carolina at Chapel Hill, Vanderbilt University
    Inventors: Aravinda M. de Silva, A. Ruklanthi de Alwis, Wahala M. P. B. Wahala, Ralph S. Baric, William B. Messer, James E. Crowe, Jr., Scott A. Smith
  • Patent number: 10106818
    Abstract: The present disclosure provides for recombinant nucleic acids, and cells and virions comprising the recombinant nucleic acids, that can be used to identify, isolate, and/or purify cells latently infected with immunodeficiency virus. A subject recombinant nucleic acid includes (a) a first nucleotide sequence encoding a first reporter polypeptide that produces a first detectable signal, where the first nucleotide sequence is operably linked to an immunodeficiency virus promoter and is translated as an early gene; and (b) a second nucleotide sequence encoding a second reporter polypeptide that produces a second detectable signal that is distinguishable from the first detectable signal, where the second nucleotide sequence is operably linked to a non-immunodeficiency virus promoter. In some aspects, the first and second nucleotide sequences are both positioned between a shared 5? long terminal repeat (LTR) and a shared 3? LTR. Also provided are related methods.
    Type: Grant
    Filed: August 14, 2014
    Date of Patent: October 23, 2018
    Assignee: The J. David Gladstone Institutes
    Inventors: Eric M. Verdin, Vincenzo Calvanese
  • Patent number: 10100091
    Abstract: The present disclosure relates to novel fusion proteins that bind to the HIV-1 gp120 antigen. The present disclosure also relates to nucleic acids, plasmids and host cells that comprise a sequence that encodes the fusion proteins of the disclosure. The fusion proteins of the disclosure can be used in applications to detect the presence of HIV-1 gp120 protein, to detect an HIV-1 infection and to monitor treatment of an HIV-1 infection.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: October 16, 2018
    Inventor: Shengxi Chen
  • Patent number: 10093720
    Abstract: The present invention relates to an exceptionally broad and potent neutralizing antibody which may comprise cross-clade neutralizing coverage of 83% at a median IC50 of 0.003 ?g/ml, compositions containing the same and uses thereof.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: October 9, 2018
    Inventors: Dennis R. Burton, Marit J. van Gils, Wayne Koff, Pascal R. G. Poignard, Rogier W. Sanders, Melissa D. J. S. Simek-Lemos, Devin Sok
  • Patent number: 10053496
    Abstract: The present application relates to methods of producing exosomes. The application also provides a method for preparing a protein composition comprising culturing an exosome-producing cell expressing a Nef-fusion protein comprising a Nef-derived peptide fused to a protein of interest; isolating exosomes from the exosome-producing cell culture; and purifying the protein of interest from the isolated exosomes. The application further discloses compositions that comprise exosomes containing the Nef-fusion protein, as well as methods of using the Nef-fusion protein and exosomes containing the Nef-fusion protein.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: August 21, 2018
    Inventors: Vincent Craig Bond, Michael Powell, Ming Bo Huang, Syed Ali
  • Patent number: 9175077
    Abstract: The invention relates to nucleotides encoding therapeutic polypeptides and fragments thereof isolated from beta-human chorionic gonadotropin (?-hCG) found in human early pregnancy urine, now synthetically produced and designated Maternin. The therapeutic polypeptides and their functional equivalents are useful in treating and/or preventing various medical conditions. Examples of therapeutic effects of the therapeutic polypeptides include anti-HIV, anti-cancer, anti-wasting, prohematopoietic (e.g., anemias, radiation-mediated bone marrow damage, and trauma-mediated blood loss), and anti-angiogenic effects. The invention also provides pharmaceutical compositions comprising the therapeutic polypeptides, as well as methods for using the therapeutic polypeptides, functional equivalents and/or pharmaceutical compositions in the treatment and/or prevention of such medical conditions.
    Type: Grant
    Filed: June 13, 2011
    Date of Patent: November 3, 2015
    Inventors: Robert C. Gallo, Joseph Bryant, Yanto Lunardi-Iskandar
  • Patent number: 9011875
    Abstract: The present invention relates to mosaic HIV-1 group M Gag sequences and to a composition comprising same.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: April 21, 2015
    Assignees: Los Alamos National Security, LLC, Beth Israel Deaconess Medical Center, Duke University, The University of Alabama at Birmingham Research Foundation
    Inventors: Bette T. Korber, Simon Perkins, Tanmoy Bhattacharya, William M. Fischer, James Theiler, Norman Letvin, Barton F. Haynes, Beatrice H. Hahn, Karina Yusim, Carla Kuiken
  • Patent number: 8865876
    Abstract: Engineered lectins and methods of using such reagents for both preventing and treating a broad array of viral infections are provided. The lectins of the invention are engineered in two ways, first through the enhancement of the natural mode of action of lectins against viruses through linked multimerization, and second through the creation of a new class of reagents, hereinafter referred to as a “lectibody” or “lectibodies”, that engage host immune function in addition to simply binding glycosylated viral proteins via the combination of a lectin and the Fc region of an antibody in order to drive Fc-mediated effector functions including ADCC (antibody-dependent cell-mediated cytotoxicity), increased half-life, complement-dependent cytotoxicity (CDC), and antibody-dependent cell-mediated phagocytosis (ADCP) in response to a lectin-mediated carbohydrate-binding event.
    Type: Grant
    Filed: June 2, 2009
    Date of Patent: October 21, 2014
    Assignee: California Institute of Technology
    Inventors: Stephen L. Mayo, Jennifer Keeffe, Alex L. Perryman
  • Patent number: 8858946
    Abstract: GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving an anti-GBV-C antibody or other GBV-C binding agent, or a GBV-C antigen, for inhibiting and treating HIV infections.
    Type: Grant
    Filed: July 24, 2008
    Date of Patent: October 14, 2014
    Assignees: The University of Iowa Research Foundation, The United States of America, as represented by the Secretary of the Department of Veterans Affairs
    Inventors: Jack T. Stapleton, Jinhua Xiang, Donna Klinzman, James H. McLinden
  • Patent number: 8841068
    Abstract: The present invention provides compositions and methods related to determining the severity of viral infections and identifying antiviral agents. In certain embodiments, the invention comprises determining the expression level of APOBEC-1 related proteins, where the expression level of APOBEC-1 related proteins is an indicator for disease severity and/or effectiveness of a potential antiviral agent. In one embodiment, the present invention provides for a method of screening for an antiviral agent.
    Type: Grant
    Filed: February 13, 2006
    Date of Patent: September 23, 2014
    Assignee: University of Rochester
    Inventors: Harold C. Smith, Xia Jin, Andrew Brooks
  • Patent number: 8840890
    Abstract: The present application provides methods for producing human monoclonal antibodies without using hybridoma technology, antibodies produced used the described methods, and methods for using the antibodies to treat or prevent disease conditions (e.g., infection by pathogens such as the Human Immunodeficiency Virus).
    Type: Grant
    Filed: November 12, 2009
    Date of Patent: September 23, 2014
    Assignee: University of Maryland, Baltimore
    Inventors: George K. Lewis, Yongjun Guan
  • Patent number: 8795682
    Abstract: Embodiments of the present disclosure encompasses virus-like particles, methods of making virus-like particles, including expression vectors, wherein the virus-like particles may comprise enhanced levels of capsid-bound a chimeric HN-Env polypeptide compared to VLPs derived from unmodified HIV-env polypeptides. Embodiments of the virus-like particle may have Env-specific epitopes exposed on the outer surface thereof. In one embodiment, the Env-specific epitopes exposed on the outer surface of the virus-like particle may specifically bind with an anti-HIV-Env specific antibody. Embodiments of the disclosure further includes methods of generating an antibody specific to an epitope of an HIV-Env polypeptide, comprising delivering to an animal or a human an effective amount of a suspension of virus-like particles comprising a chimeric HIV-Eny polypeptide, thereby inducing the formation of an antibody specific to an epitope of an HIV-1 eny polypeptide.
    Type: Grant
    Filed: May 2, 2008
    Date of Patent: August 5, 2014
    Assignees: Emory University, The UAB Research Foundation, Novavax, Inc.
    Inventors: Richard W. Compans, Baozhong Wang, Beatrice Hahn, Weimin Liu, Gale Smith, Peter Pushko
  • Patent number: 8795687
    Abstract: The present invention provides virus-like particles (VLP) highly secreting or producing signal peptide obtained by altering a signal sequence derived from West Nile virus (WNV), the signal peptide, a WNV VLP secretion expression vector containing a nucleic acid encoding prM protein and E protein, a WNP VLP highly secreting or producing animal cell line harboring the vector, a WNV vaccine containing WNV VLP obtained by the cell line as an active ingredient, and a WNV DNA vaccine containing the VLP secretion expression vector as an active ingredient.
    Type: Grant
    Filed: November 7, 2008
    Date of Patent: August 5, 2014
    Assignees: Japan as Represented by the Director-General of National Institute of Infections Diseases, The Research Foundation for Microbial Diseases of Osaka University
    Inventors: Asato Kojima, Hidehiro Takahashi, Toyokazu Ishikawa
  • Patent number: RE45123
    Abstract: The invention provides compositions featuring an attenuated dengue virus mutant or an attenuated chimeric dengue virus mutant.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: September 9, 2014
    Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney, Ching-Juh Lai